In addition, there was negative correlation between FEZF1-AS1 expression and clinical outcome in breast cancer [22], liver cancer [23,24], gastric cancer [25,27], pancreatic cancer [30,31], ovarian cancer [32], osteosarcoma [34] and nasopharyngeal carcinoma [35]. This evidence concerns the gene FEZF1 and gastric cancer.